Condition: Primary Sclerosing Cholangitis · Inflammatory Bowel Diseases · Sponsor: University of Birmingham
FARGO is a randomised, phase IIa, multi-centre, placebo-controlled trial to compare Faecal Microbiota Transplant (FMT) with placebo in patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease.
This description comes directly from the study's public registry record.
Helen Coulthard · +44 (0121) 3718198 · FARGO@trials.bham.ac.uk
Anna Rowe · +44 (0121) 3718117 · FARGO@trials.bham.ac.uk
Always discuss trial participation with your own doctor first.
| Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust | Birmingham, United Kingdom | Recruiting |
| St Mark's Hospital, London North West University Healthcare NHS Trust | London, United Kingdom | Recruiting |
| Royal Free Hospital, Royal Free London NHS Foundation Trust | London, United Kingdom | Recruiting |
| King's College Hospital, King's College Hospital NHS Foundation Trust | London, United Kingdom | Recruiting |
| John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust | Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06286709